EE200400048A - Atorvastatiinkaltsiumi kristalsed vormid VI ja VII - Google Patents
Atorvastatiinkaltsiumi kristalsed vormid VI ja VIIInfo
- Publication number
- EE200400048A EE200400048A EEP200400048A EEP200400048A EE200400048A EE 200400048 A EE200400048 A EE 200400048A EE P200400048 A EEP200400048 A EE P200400048A EE P200400048 A EEP200400048 A EE P200400048A EE 200400048 A EE200400048 A EE 200400048A
- Authority
- EE
- Estonia
- Prior art keywords
- vii
- crystalline forms
- atorvastatin calcium
- atorvastatin
- calcium
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN620MA2001 | 2001-07-30 | ||
| PCT/US2002/000431 WO2003011826A1 (en) | 2001-07-30 | 2002-01-07 | Crystalline forms vi and vii of atorvastatin calcium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EE200400048A true EE200400048A (et) | 2004-04-15 |
Family
ID=35160889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200400048A EE200400048A (et) | 2001-07-30 | 2002-01-07 | Atorvastatiinkaltsiumi kristalsed vormid VI ja VII |
Country Status (19)
| Country | Link |
|---|---|
| EP (2) | EP1414796A1 (pl) |
| JP (1) | JP2005500351A (pl) |
| KR (1) | KR20040019043A (pl) |
| CN (1) | CN100471836C (pl) |
| AU (1) | AU2002255479B2 (pl) |
| BG (1) | BG108518A (pl) |
| BR (1) | BR0211488A (pl) |
| CA (1) | CA2454500C (pl) |
| CZ (1) | CZ2004126A3 (pl) |
| EE (1) | EE200400048A (pl) |
| HR (1) | HRP20040077A2 (pl) |
| IL (2) | IL159626A0 (pl) |
| MX (1) | MXPA04000889A (pl) |
| NO (1) | NO20040390L (pl) |
| NZ (1) | NZ530785A (pl) |
| PL (1) | PL368647A1 (pl) |
| RU (1) | RU2304139C2 (pl) |
| WO (1) | WO2003011826A1 (pl) |
| ZA (1) | ZA200400573B (pl) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| KR100704213B1 (ko) * | 2000-11-03 | 2007-04-10 | 테바 파마슈티컬 인더스트리즈 리미티드 | 아토르바스타틴 헤미-칼슘 ｖｉｉ형 |
| US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| CA2622477A1 (en) * | 2000-12-27 | 2002-07-04 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of atorvastatin |
| CA2475864A1 (en) * | 2002-02-15 | 2003-08-28 | Teva Pharmaceutical Industries Ltd. | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix |
| HRP20040767A2 (en) | 2002-02-19 | 2004-12-31 | Teva Pharma | Desolvating solvates of atorvastatin hemi-calcium |
| WO2004050618A2 (en) * | 2002-11-28 | 2004-06-17 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
| EP1424324A1 (en) * | 2002-11-28 | 2004-06-02 | Teva Pharmaceutical Industries Limited | Crystalline form F of Atorvastatin hemi-calcium salt |
| US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| WO2005090301A1 (en) * | 2004-03-17 | 2005-09-29 | Ranbaxy Laboratories Limited | Crystalline form of atorvastatin hemi calcium |
| WO2005092852A1 (en) | 2004-03-17 | 2005-10-06 | Ranbaxy Laboratories Limited | Process for the production of atorvastatin calcium in amorphous form |
| CA2573969C (en) * | 2004-07-16 | 2014-02-04 | Lek Pharmaceuticals D.D. | Oxidative degradation products of atorvastatin calcium |
| JP2008506764A (ja) | 2004-07-20 | 2008-03-06 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | ［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β、δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）の新規形態 |
| WO2006037125A1 (en) | 2004-09-28 | 2006-04-06 | Teva Pharmaceutical Industries Ltd. | Process for preparing forms of atorvastatin calcium substantially free of impurities |
| WO2006046109A1 (en) | 2004-10-28 | 2006-05-04 | Warner-Lambert Company Llc | Process for forming amorphous atorvastatin |
| WO2006048894A1 (en) * | 2004-11-05 | 2006-05-11 | Morepen Laboratories Limited | Novel crystalline forms of atorvastatin calcium and processes for preparing them. |
| US8080672B2 (en) | 2005-12-13 | 2011-12-20 | Teva Pharmaceutical Industries Ltd. | Crystal form of atorvastatin hemi-calcium and processes for preparation thereof |
| WO2009007856A2 (en) * | 2007-07-11 | 2009-01-15 | Actavis Group Ptc Ehf | Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium |
| KR20120011249A (ko) | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
| CN104983702A (zh) * | 2015-07-23 | 2015-10-21 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂 |
| CN108157405B (zh) * | 2018-02-06 | 2020-10-02 | 上海应用技术大学 | 一种灭蟑螂饵剂及其制备方法和应用 |
| WO2025147589A1 (en) | 2024-01-05 | 2025-07-10 | Osanni Bio, Inc. | Implants, compositions, and methods for treating retinal diseases and disorders |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5245047A (en) | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5216174A (en) | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5124482A (en) | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
| US5097045A (en) | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5003080A (en) | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
| US5149837A (en) | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5248793A (en) | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5103024A (en) | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5155251A (en) | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
| US5298627A (en) | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| IL109570A0 (en) * | 1993-05-17 | 1994-08-26 | Fujisawa Pharmaceutical Co | Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof |
| HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| GEP20002029B (en) | 1995-07-17 | 2000-04-10 | Warner Lambert Company Us | (54) Crystalline [R-(R*,R*,]–2-(4-Fluorophenyl)-Beta,Delta-Dihydroxy-5-(1-Methyl-Ethyl)-3-Phenyl–4-{Phenylamino) Carbonyl} - 1H - Pyrrole - 1 - Heptanoic Acid Hemi Calcium Salt (Atorvastatin) |
| US6087511A (en) | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
| US5929156A (en) | 1997-05-02 | 1999-07-27 | J.M. Huber Corporation | Silica product for use in elastomers |
| HU226640B1 (en) | 1999-10-18 | 2009-05-28 | Egis Gyogyszergyar Nyilvanosan | Process for producing amorphous atorvastatin calcium salt |
| ES2234699T3 (es) | 1999-11-17 | 2005-07-01 | Teva Pharmaceutical Industries Ltd. | Forma polimorfica de atorvastatina calcio. |
| KR100704213B1 (ko) * | 2000-11-03 | 2007-04-10 | 테바 파마슈티컬 인더스트리즈 리미티드 | 아토르바스타틴 헤미-칼슘 ｖｉｉ형 |
| PL362981A1 (pl) * | 2000-11-16 | 2004-11-02 | Teva Pharmaceutical Industries Ltd. | Hydroliza estrów kwasu [R( R*, R*)-2-(4-fluorofenylo)-beta,delta-dihydroksy-5-(1-metyloetylo)-3-fenylo-4-[( fenyloamino) karbonylo]-1H-pirolo-1-heptanowego wodorotlenkiem wapnia |
| IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| CA2622477A1 (en) * | 2000-12-27 | 2002-07-04 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of atorvastatin |
| WO2002057229A1 (en) * | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
-
2002
- 2002-01-07 AU AU2002255479A patent/AU2002255479B2/en not_active Ceased
- 2002-01-07 RU RU2004103470/04A patent/RU2304139C2/ru not_active IP Right Cessation
- 2002-01-07 NZ NZ530785A patent/NZ530785A/en not_active IP Right Cessation
- 2002-01-07 CN CNB028150708A patent/CN100471836C/zh not_active Expired - Fee Related
- 2002-01-07 IL IL15962602A patent/IL159626A0/xx unknown
- 2002-01-07 CZ CZ2004126A patent/CZ2004126A3/cs unknown
- 2002-01-07 KR KR10-2004-7000093A patent/KR20040019043A/ko not_active Ceased
- 2002-01-07 PL PL02368647A patent/PL368647A1/pl unknown
- 2002-01-07 EP EP02724877A patent/EP1414796A1/en not_active Withdrawn
- 2002-01-07 WO PCT/US2002/000431 patent/WO2003011826A1/en not_active Ceased
- 2002-01-07 EE EEP200400048A patent/EE200400048A/xx unknown
- 2002-01-07 JP JP2003517018A patent/JP2005500351A/ja active Pending
- 2002-01-07 EP EP10010845A patent/EP2292600A1/en not_active Withdrawn
- 2002-01-07 HR HR20040077A patent/HRP20040077A2/xx not_active Application Discontinuation
- 2002-01-07 CA CA002454500A patent/CA2454500C/en not_active Expired - Fee Related
- 2002-01-07 MX MXPA04000889A patent/MXPA04000889A/es active IP Right Grant
- 2002-01-07 BR BR0211488-7A patent/BR0211488A/pt not_active Application Discontinuation
-
2003
- 2003-12-29 IL IL159626A patent/IL159626A/en not_active IP Right Cessation
-
2004
- 2004-01-09 BG BG108518A patent/BG108518A/xx unknown
- 2004-01-26 ZA ZA200400573A patent/ZA200400573B/en unknown
- 2004-01-29 NO NO20040390A patent/NO20040390L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BG108518A (en) | 2004-08-31 |
| CA2454500C (en) | 2009-11-10 |
| ZA200400573B (en) | 2005-05-11 |
| CZ2004126A3 (cs) | 2004-12-15 |
| IL159626A (en) | 2013-04-30 |
| HRP20040077A2 (en) | 2004-06-30 |
| AU2002255479B2 (en) | 2008-09-11 |
| RU2304139C2 (ru) | 2007-08-10 |
| EP2292600A1 (en) | 2011-03-09 |
| MXPA04000889A (es) | 2004-06-03 |
| KR20040019043A (ko) | 2004-03-04 |
| BR0211488A (pt) | 2004-08-17 |
| RU2004103470A (ru) | 2005-06-20 |
| JP2005500351A (ja) | 2005-01-06 |
| CA2454500A1 (en) | 2003-02-13 |
| NZ530785A (en) | 2005-10-28 |
| CN100471836C (zh) | 2009-03-25 |
| PL368647A1 (pl) | 2005-04-04 |
| CN1537098A (zh) | 2004-10-13 |
| NO20040390L (no) | 2004-01-29 |
| IL159626A0 (en) | 2004-06-01 |
| EP1414796A1 (en) | 2004-05-06 |
| WO2003011826A1 (en) | 2003-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE200400048A (et) | Atorvastatiinkaltsiumi kristalsed vormid VI ja VII | |
| HUP0302797A3 (en) | Preparation of non-crystalline atorvastatin calcium | |
| EE200300459A (et) | Uued spirotritsüklilised derivaadid ja nende kasutamine fosfodiesteraas-7 inhibiitoritena | |
| PT1169314E (pt) | Base cristalina de citalopram | |
| AR028253A1 (es) | Inhibidores de la glucogeno fosforilasa | |
| NO20031986D0 (no) | Atorvastatinhemi-kalsium for VII | |
| PT1411923E (pt) | Composições farmacêuticas de amlodipina e atorvastatina | |
| EE200200328A (et) | Multi kompositsioon ja meetod | |
| PL352828A1 (pl) | Wspólna sól amlodypiny i atorwastatyny | |
| DE50212455D1 (de) | Verwendung von Dimerdiolen | |
| EE200100135A (et) | EtO2C-CH2-(R)Cgl-Aze-Pab-OH kristalsed vormid | |
| ATE391502T1 (de) | Kristalline formen von fluvastatin-natrium | |
| NO20042433L (no) | Syntese og rensing av valasyklovir | |
| PT1432685E (pt) | Hidratos cristalinos de derivados de anilida do acido nicotinico e de benzoilanilida | |
| EE200100631A (et) | Amlodipiini ja atorvastatiini ühised eelravimid | |
| DE60107074D1 (de) | Kristallin form ii von cabergolin | |
| IS7128A (is) | Hreinsun á zaleploni og kristölluð form þess | |
| ATE259946T1 (de) | Dübel zur befestigung an hohl- und an vollbaustoffen | |
| EP1290135A4 (en) | HY2 FAMILY OF BILINE REDUCTORS | |
| DE60220993D1 (de) | Kristalline zusammensetzungen von dotiertem aluminiumphosphat | |
| AR028070A1 (es) | Sintesis de compuestos de ciclohexendimetanol o ciclohexandimetanol | |
| PT1392670E (pt) | Derivados substituidos de c-furan-2-il-metilamina e c-tiofen-2-il-metilamina | |
| PT1310615E (pt) | Elemento de degrau de uma tribuna | |
| FI20012295A0 (fi) | Hyvyysluku | |
| AU2002322445A1 (en) | Crystals and structures of arnb aminotransferases |